Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

Journal of Cell Science

Volumn 121, Issue 20, 2008, Pages 3487-3495

  Nowak, Dawid G ^a   Woolard, Jeanette ^a   Amin, Elianna Mohamed ^b   Konopatskaya, Olga ^a   Saleem, Moin A ^c   Churchill, Amanda J ^a   Ladomery, Michael R ^b   Harper, Steven J ^a   Bates, David O ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Clk1 sty (CLK1); CLK4; IGF1; Splicing; SRp55; TGF 1; VEGF; VEGF165b; VEGFxxxb

Indexed keywords

DOCKING PROTEIN; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN SRP55; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

3' UNTRANSLATED REGION; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL SELECTION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; EPITHELIUM CELL; EXON; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA SPLICING; STOP CODON;

ALTERNATIVE SPLICING; ANGIOGENESIS INHIBITORS; CELLS, CULTURED; EXONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RNA SPLICE SITES; RNA-BINDING PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56349136033     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.016410     Document Type: Article

References (66)

1. Asano-Kato, N., Fukagawa, K, Okada, N., Kawakita, T., Takano, Y., Dogru, M., Tsubota, K. and Fujishima, H. (2005) TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. Exp. Eye Res. 80, 555-560.
2. Bakin, A. V., Safina, A., Rinehart, C, Daroqui, C., Darbary, H. and Helfman, D. M. (2004). A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol. Biol. Cell 15, 4682-4694.
3. Bates, D. O., Cui, T. G., Doughty, J. M., Winkler, M., Sugiouo, M., Shields, J. D., Peat, D., Glilatt, D. and Harper, S. J. (2002). VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123-4131.
4. Bates, D. O., MacMillan, P. P., Manjaly, J. G., Qiu, Y., Hudson, S. J., Bevan, H. S., Hunter, A. J., Soothill, P. W., Read, M., Donaldson, L. F. et al. (2006). The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. Clin. Sci. 110, 575-585.
5. Blaustein, M., Pelisch, F., Tanos, T., Munoz, M. J., Wengier, D., Quadrana, L., Sanford, J. R., Muschietti, J. P., Kornblihtt, A. R., Caceres, J. F. et al. (2005). Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat. Struct. Mol. Biol. 12, 1037-1044.
6. Caceres, J. F. and Kornblihtt, A. R. (2002). Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18, 186-193.
7. Carmeliet, P. (2000). VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat. Med. 6, 1102-1103.
8. Cube Suarez, S., Pieren, M., Cariolato, L., Arn, S., Hoffmann, U., Bogucki, A., Manlius, C., Wood, J. and Ballmer-Hofer, K. (2006). A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell. Mol. Life Sci 63, 2067-2077.
9. Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R. and Dake, M. D. (2001). Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 7, 425-429.
10. Charnock-Janes, D. S., Macpherson, A. M., Archer, D. F., Leslie, S., Makkink, W. K., Sharkey, A. M. and Smith, S. K. (2000). The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum. Reprod. 15 Suppl. 3, 85-95.
11. Chomczynski, P. and Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
12. Cohen, C. D., Doran, P. P., Blattuer, S. M, Merkle, M., Wang, G. Q., Schmid, H., Mathieson, P. W., Saleem, M. A., Henger, A., Rastaldi, M. P. et al. (2005). Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor. J. Am. Soc. Nephrol. 16, 1958-1965.
13. Cramer, P., Caceres, J. F., Cazalla, D., Kadener, S., Muro, A. F., Baralle, F. E. and Kornblihtt, A. R. (1999). Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. Mol. Cell 4, 251-258,
14. Cui, T. G., Foster, R. R., Saleem, M., Mathieson, P. W., Gillatt, D. A., Bates, D. O. and Harper, S. J. (2004). Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF 165b) mRNA and protein. Am. J Physiol. Renal Physiol. 286, F767-F773.
15. Dowhan, D. H., Hong, E. P., Auboeuf, D., Dennis, A. P., Wilson, M. M., Berget, S. M. and O'Malley, B. W. (2005). Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol. Cell 17, 429-439.
16. Eyetech Study Group (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110, 979-986.
17. Ferrara, N. and Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25.
18. Finkenzeller, G., Sparacio, A., Technau, A., Marme, D. and Siemeister, G. (1997). Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15, 669-676.
19. Folkman, J. (1985). Tumor angiogenesis. Adv. Cancer Res. 43, 175-203.
20. Goad, D. L., Rubin, J., Wang, H., Tashjian, A. H., Jr and Patterson, C. (1996). Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by iusulin-like growth factor I. Endocrinology 137, 2262-2268.
21. Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Jr, Feinsod, M. and Guyer, D. R. (2004). Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816,
22. Herrera, B., Fernandez, M., Roncero, C., Ventura, J. J., Porras, A., Valladares, A., Benito, M. and Fabregat, I. (2001) Activation of p38MAPK by TGF-beta in feta1 rat bepatocytes requires radical oxygen production, but is dispensable for cell death. FEBS Lett. 499, 225-229.
23. Hertel, K. J., Lynch, K. W. and Manialis, T. (1997). Common themes in the function of transcription and splicing enhancers. Curr. Opin. Cell Biol. 9, 350-357.
24. Hirose, Y., Tacke, R. and Manley, J. L. (1999). Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. Genes Dev. 13, 1234-1239.
25. Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D. W. (1991). The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806-1814.
26. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E. et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
27. Jin, W. and Cote, G. J. (2004). Enhancer-dependent splicing of FGFR1 alpha-exon is repressed by RNA interference-mediated down-regulation of Sgp55. Cancer Res. 64, 8901-8905.
28. Kalnina, Z., Zayakin, P., Silina, K. and Line, A. (2005). Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42, 342-357.
29. Keck, R. G., Berleau, L., Harris, R. and Keyt, B. A. (1997). Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. Arch. Biochem. Biophys. 344, 103-113.
30. Koenigsberger, C., Chicca, J. J., 2nd, Amoureux, M. C., Edelman, G. M. and Jones, F. S. (2000). Differential regulation by multiple promoters of the gene encoding the neuron-restrictive silencer factor. Proc. Natl. Acad. Sci. USA 97, 2291-2296.
31. Konopatskaya, O., Churchill, A. J., Harper, S. J., Bates, D. O. and Gardiner, T. A. (2006). VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis. 12, 626-632.
32. Kornblihtt, A. R. (2005). Promoter usage and alternative splicing. Curr. Opin. Cell Biol. 17, 262-268.
33. Kotsuji-Maruyama, T., Imakado, S., Kawachi, Y. and Otsuka, F. (2002). PDGF-BB induces MAP kinase phosphorylation and VEGF expression in neurofibroma-derived cultured cells from patients with neurofibromatosis 1. J. Dermatol. 29, 713-717.
34. Lai, M. C., Lin, R. I. and Tarn, W. Y. (2003). Differential effects of hyperphosphorylation on splicing factor SRp55. Biochem. J. 371, 937-945.
35. Lechuga, C. G., Hernandez-Nazara, Z. H., Dominguez Rosales, J. A., Morris, E. R., Rincon, A. R., Rivas-Estilla, A. M., Esteban-Gamboa, A. and Rojkind, M. (2004). TGF-beta1 modulates matrix mctalloproteinase-13 expression in hepatic stellate cells by complex mechanisms involving p38MAPK, PI3-kinase, AKT, and p70S6k. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G974-G987.
36. Li, H., Yonekura, H., Kim, C. H., Sakurai, S., Yamamoto, Y., Takiya, T., Futo, S., Watanabe, T. and Yamamoto, H. (2004). Possible participation of pICln in the regulation of angiogenesis through alternative splicing of vascular endothelial growth factor receptor mRNAs. Endothelium 11, 293-300.
37. Li, J., Perrella, M. A., Tsai, J. C., Yet, S. F., Hsieh, C. M., Yoshizumi, M., Patterson, C., Endege, W. O., Zhou, F. and Lee, M. E. (1995). Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J. Biol. Chem. 270, 308-312.
38. Lin, J. C., Hsu, M. and Tarn, W. Y. (2007). Cell stress modulates the function of splicing regulatory protein RBM4 in translation control. Proc. Natl. Acad. Sci. USA 104, 2235-2240.
39. Matlin, A. J., Clark, F. and Smith, C. W. (2005). Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell. Biol. 6, 386-398.
40. Matsumoto, K., Ohi, H. and Kanmatsuse, K. (1997). Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 77, 212-218.
41. McCarthy, M. (2003). Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361, 1959.
42. Misteli, T., Caceres, J. F. and Spector, D. L. (1997). The dynamics of a pre-m-RNA splicing factor in living cells. Nature 387, 523-527.
43. Mukhopadhyay, D., Tsiokas, L., Zhou, X. M., Foster, D., Brugge, J. S. and Sukhatme, V. P. (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577-581.
44. Neufeld, G., Cohen, T., GitayGoren, H., Poltorak, Z., Tessler, S., Sharon, R., Gengrinovitch, S. and Levi, B. Z. (1996). Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer and Metastasis Rev. 15, 153-158.
45. Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22.
46. Patterson, C., Perrella, M. A., Endege, W. O., Yoshizumi, M., Lee, M. E. and Haber, E. (1996). Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J. Clin. Invest. 98, 490-496.
47. Perkett, E. A. and Klekamp, J. G. (1998). Vascular endothelial growth factor expression is decreased in rat lung following exposure to 24 or 48 hours of hyperoxia: implications for endothelial cell survival. Chest 114, 52S-53S.
48. Perrin, R. M., Konopatskaya, O., Qiu, Y., Harper, S., Bates, D. O. and Churchill, A. J. (2005). Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48, 2422-2427.
49. Pertovaara, L., Kaipainen, A., Mustonen, T., Orpana, A., Ferrara, N., Saksela, O. and Alitalo, K. (1994). Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol. Chem. 269, 6271-6274.
50. Prasad, J., Colwill, K., Pawson, T. and Manley, J. L. (1999). The protein kinase Clk/Sty directly modulates SR protein activity: beth hyper- and hypophosphorylation inhibit splicing. Mol. Cell Biol. 19, 6991-7000.
51. Pritchard-Jones, R. O., Dunn, D. B., Qiu, Y., Varey, A. H., Orlando, A., Rigby, H., Harper, S. J. and Bates, D. O. (2007). Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br. J. Cancer 97, 223-230.
52. Qiu, Y., Bevan, H., Weeraperuma, S., Wratting, D., Murphy, D., Neal, C. R., Bates, D. O. and Harper, S. J. (2007). Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB J. 22, 1104-1112.
53. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T. and Kerbel, R. S. (1995). Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575-4580.
54. Rennel, E., Waine, E., Guan, H., Schuler, Y., Leenders, W., Woolard, J., Sugiono, M., Gillatt, D., Kleinerman, E., Bates, D. et al. (2008a). The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br. J. Cancer 98, 1250-1257.
55. 165b protein is an effective anti-cancer agent in mice. Eur. J. Cancer 44, 1883-1894.
56. Rosenthal, R. A., Megyesi, J. F., Henzel, W. J., Ferrara, N. and Folkman, J. (1990). Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 4, 53-59.
57. Saleem, M. A., O'Hare, M. J., Reiser, J., Coward, R. J., Inward, C. D., Farren, T, Xing, C. Y., Ni, L., Mathieson, P. W. and Mundel, P. (2002). A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J. Am. Soc. Nephrol. 13, 630-638.
58. Schumacher, V. A., Jeruschke, S., Eitner, F., Backer, J. U., Pitschke, G., Ince, Y., Miner, J. H., Leuschner, I., Engers, R., Everding, A. S. et al. (2007). Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J. Am. Soc. Nephrol. 18, 719-729.
59. Shwelki, D., Itin, A., Soffer, D. and Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845
60. Smith, C. W. (2005). Alternative splicing - when two's a crowd. Cell 123, 1-3,
61. Sone, H., Kawakami, Y., Okuda, Y., Kondo, S., Hanatani, M., Suzuki, H. and Yamashita, K. (1996). Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Biochem. Biophys. Res Commun. 221, 193-198.
62. van der Houven van Oordt, W., Diaz-Meco, M. T., Lozano, J., Krainer, A. R., Moscat, J. and Caceres, J. F. (2000). The MKK(3/ 6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J. Cell Biol. 149, 307-316.
63. Varey, A. H., Rennel, E. S., Qiu, Y., Bevan, H. S., Perrin, R. M., Raffy, S., Dixon, A. R., Paraskeva, C., Zaccheo, O., Hassan, A. B. et al. (2008). VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br. J. Cancer 98, 1366-1379.
64. Venables, J. P. (2006). Unbalanced alternative splicing and its significance in cancer. BioEssays 28, 378-386.
65. Woolard, J., Wang, W. Y., Bevan, H. S., Qiu, Y., Morbidelli, L., Pritchard-Jones, R. O., Cui, T. G., Sugiono, M., Waine, E., Perrin, R. et al. (2004). VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822-7835.
66. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X. and Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434.